Predictors of severity in severe respiratory infection in children with COVID-19 respiratory infection in a developing country

J Med Virol. 2023 Feb;95(2):e28453. doi: 10.1002/jmv.28453.

Abstract

On March 11, 2020, the WHO declared the COVID-19 pandemic. This name was given to the disease caused by the SARS-CoV 2 virus at its outbreak in December 2019 in Wuhan, Hubei, China. In Colombia, a significant number of cases have been confirmed. The aim of this study was to evaluate children with respiratory symptoms caused by SARS-CoV2 infection, identifying independent predictors of risk of having a severe illness, thus leading to an early approach and intervention in our patients, especially in children with comorbidities. An analytical cross-sectional study was conducted between April 1, 2020 and March 31, 2021 at a fourth-level referral institution in Bogotá on patients under 18 years of age with respiratory symptoms and a COVID-19 diagnosis confirmed in the laboratory. An explanatory binary logistic regression model was performed with an outcome variable of admission to the intensive care unit. A total of 385 children were included in the study, with ages between 9 months and 17 years of age; 50.1% were male, and the ICR was 9.75 years. 41.6% had some comorbidity, 13.5% were admitted to the pediatric ICU, and 3.6% of the total number of patients died. The predictor variables were: use of antibiotics in the first 24 h, neurological comorbidity, and consolidation shown in the chest X-ray. This explains 38.7% of the variability of the variable. In this cohort of patients with COVID-19-associated respiratory symptoms, we identified predictors of severity, so we consider that these patients require a risk approach that allows timely and adequate care.

Keywords: COVID-19; pediatric SARS-CoV-2; pediatric intensive care unit.

MeSH terms

  • Adolescent
  • COVID-19 Testing
  • COVID-19*
  • Child
  • Cross-Sectional Studies
  • Developing Countries
  • Female
  • Humans
  • Infant
  • Intensive Care Units, Pediatric
  • Male
  • Pandemics
  • RNA, Viral
  • SARS-CoV-2

Substances

  • RNA, Viral